Reach Us +441467840001
Interview | Daniel J CanneynbspMedicinal Chemistry
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Daniel J Canney
Daniel J Canney

Daniel J Canney
Associate Professor
Department of Pharmaceutical Science
Temple University

Read Interview session with Daniel J Canney


Daniel J. Canny received his Ph.D in the Department of Medicinal Chemistry, Temple University.He got his Post Doctoral Fellowship from the Department of Pharmacology and Molecular Biology, University of Washington. He is working as an Associate Professor of Medicinal Chemistry, Temple University from 1993.

Research Interest

Research interests include the synthesis, characterization and evaluation of novel ligands for muscarinic, nicotinic, retinoic acid receptor subtypes and amino/amido-lactone derivatives as potential anticonvulsant agents. A recent interest involves the development of inhibitors of the HMGB-1/DNA interaction using glycyrrhetinic acid as a lead. These compounds are evaluated in a variety of in vivo and in vitro assays through collaboration with investigators in the School of Pharmacy and the School of Medicine.


1. How many years have you been practicing and/or performing research?
Over 25 years doing research in an academic setting as a professor of medicinal chemistry.

2. What is the research topic you are working on now?
Design, synthesis and evaluation of ligands for serotonin receptor subtypes.

3. What makes an article top quality?
Hypothesis driven research topic in which the experimental design is well thought out and the interpretation of data is accurately described.

4. What are the qualities you look for in an article?
Interesting topic, solid experimental design, and interesting outcome that moves the knowledge in an area forward.

5. Do you have any research funding (NIH or other national funding) now?
Not at the present time but will be submitting in the near future.

6. When did you become an editor of OMICS Journal?
Since 2004.

7. What is your greatest career accomplishment?
Temple University, Outstanding Faculty Service Award (October, 2012).

8. How does the research published percolate through to practitioners?
Our research involves the design and testing of lead ligands for therapeutically important receptor proteins. Following lead modification approaches to improve pharmacokinetic and pharmacodynamic properties, these molecules have potential as drug candidates for the treatment of a variety of disorders.

9. What is the purpose of serving as an editor?
Service as an editor is a means of serving/giving back to the scientific community and staying abreast of the many important development in our discipline. I do believe that the journal should give special privileges to Editorial Board members when it comes to journal access and publishing their own work.

10. Do you have any patents?
Yes, 2 recent patents involving ligands for serotonin receptors.

11. Have you contributed any editorials or papers (any types) to OMICS Journals in the past two years?
Yes, we published a paper on our work in 2014.

12. Do you plan to contribute any editorials or papers to OMICS Journals in the next year?
Yes, I hope to contribute a paper or review in 2015. I am reluctant after our recent experience with the review process.

13. Do you have any trouble with OMICS Journals in the past?
I found the review process to be slow and cumbersome. The review process took too long and there was too much confusion in correspondence between the authors and editorial staff. The fact that I was on the editorial board made no difference in the handling of our manuscript.

14. Would you recommend OMICS to your friends or colleagues?
I am reluctant following my experience last year. It would not be my first choice for a Medicinal Chemistry journal given my past experience.

15. How do you differentiate Medicinal Chemistry with other journals in the field?
Currently, I do not see a clear advantage of publishing in the journal compared to similar journals in the field. Access to my own paper is difficult even though I am on the editorial board.
There should also be special arrangements for editorial board members for access to the journal and when they publish in the journal.